SCHEMBL1637477

SCHEMBL1637477

COC(=O)C1CN(Cc2ccccn2)C(=O)N1C

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.59
SIRT1 Q96EB6 1/20 0.45
NPC1 O15118 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.42
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
ALDH1A1 P00352 2/20 0.41
LMNA P02545 1/20 0.41
CACNA1G O43497 1/20 0.41
CACNA1H O95180 1/20 0.41
CACNA1I Q9P0X4 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
FPR1 P21462 2/20 0.39
FPR2 P25090 1/20 0.39
TSHR P16473 1/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1637954 0.86 P2RX7 (0.59) P2RX7SIRT1SMN1; SMN2DDB1CRBN
SCHEMBL12724760 0.75 P2RX7 (1.00) P2RX7
Hydrochloric Acid SCHEMBL1635940 0.74 P2RX7 (0.98) P2RX7
SCHEMBL1635952 0.73 P2RX7 (0.53) P2RX7
SCHEMBL5638265 0.73 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1FPR1FPR2
SCHEMBL31148120 0.72 HSD11B1 (0.58) NPC1SMN1; SMN2ALDH1A1LMNAL3MBTL1
SCHEMBL5955659 0.72 HSD11B1 (0.58) NPC1SMN1; SMN2ALDH1A1LMNAL3MBTL1
SCHEMBL5955657 0.72 HSD11B1 (0.58) NPC1SMN1; SMN2ALDH1A1LMNAL3MBTL1
SCHEMBL28451423 0.71 L3MBTL1 (0.63) NPC1SMN1; SMN2ALDH1A1LMNAL3MBTL1
SCHEMBL21061928 0.71 L3MBTL1 (0.63) NPC1SMN1; SMN2ALDH1A1LMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932282-B2 Imidazolidine carboxamide derivatives as P2X7 modulators GLAXO GROUP LIMITED (GB) 2011-04-26 US disclosed
US-20100075968-A1 Imidazolidine Carboxamide Derivatives as P2X7 Modulators GLAXO GROUP LIMITED (GB) 2010-03-25 US disclosed
EP-2142512-A2 IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS Glaxo Group Limited (GB) 2010-01-13 EP disclosed
WO-2008119825-A2 IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS GLAXO GROUP LIMITED (GB) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075968-A1 Imidazolidine Carboxamide Derivatives as P2X7 Modulators P2RX3, P2RX7, P2RX5 P2RX7 2/4885SIRT1 592/4885NPC1 1107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.